| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1517/14656560903048967 |
| P698 | PubMed publication ID | 19527192 |
| P2093 | author name string | Ali El Solh | |
| P2860 | cites work | In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci | Q24550612 |
| Invasive methicillin-resistant Staphylococcus aureus infections in the United States | Q29616087 | ||
| Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic | Q33264142 | ||
| In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci | Q34162130 | ||
| Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. | Q34307105 | ||
| Practice guidelines for the diagnosis and management of skin and soft-tissue infections | Q34460523 | ||
| Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target | Q34510488 | ||
| Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae | Q34624359 | ||
| Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects | Q35879080 | ||
| Investigational new drugs for the treatment of resistant pneumococcal infections | Q36210902 | ||
| Can beta-lactams be re-engineered to beat MRSA? | Q36416468 | ||
| Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity | Q37030780 | ||
| Pharmacokinetic issues for antibiotics in the critically ill patient | Q37399820 | ||
| Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. | Q37733667 | ||
| In vitro selection and characterization of ceftobiprole-resistant methicillin-resistant Staphylococcus aureus | Q38899451 | ||
| In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections | Q39077347 | ||
| BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis | Q39650937 | ||
| Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections | Q39747857 | ||
| Molecular aspects of methicillin resistance in Staphylococcus aureus | Q40740211 | ||
| Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers | Q40967997 | ||
| Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers | Q40968003 | ||
| Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus | Q41092910 | ||
| Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin | Q41847350 | ||
| Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis | Q41849670 | ||
| Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin | Q42112713 | ||
| Interactions of ceftobiprole with beta-lactamases from molecular classes A to D. | Q42584480 | ||
| Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? | Q43874264 | ||
| BAL 9141, a new broad-spectrum pyrrolidinone cephalosporin: activity against clinically significant anaerobes in comparison with 10 other antimicrobials | Q43895628 | ||
| Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000) | Q44429058 | ||
| Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci | Q44655200 | ||
| In vitro activity of BAL9141 against clinical isolates of gram-negative bacteria | Q44755053 | ||
| A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections | Q46787486 | ||
| In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin | Q46792584 | ||
| Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis | Q46904137 | ||
| Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees | Q46970635 | ||
| The growing menace of community-acquired methicillin-resistant Staphylococcus aureus | Q46978005 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1675-1686 | |
| P577 | publication date | 2009-07-01 | |
| P1433 | published in | Expert Opinion on Pharmacotherapy | Q5421212 |
| P1476 | title | Ceftobiprole: a new broad spectrum cephalosporin | |
| P478 | volume | 10 |
| Q28741367 | A field guide to pandemic, epidemic and sporadic clones of methicillin-resistant Staphylococcus aureus |
| Q37708866 | Antibiotic management of febrile neutropenia: current developments and future directions |
| Q34156349 | Antibiotics and bacterial resistance in the 21st century |
| Q26796463 | Ceftobiprole for the treatment of pneumonia: a European perspective |
| Q35026567 | Emerging agents to combat complicated and resistant infections: focus on ceftobiprole |
| Q37670186 | Emerging drugs in sepsis. |
| Q36913239 | Epidemiology of antimicrobial resistance in bloodstream infections |
| Q92304798 | Mechanisms of action and antimicrobial activity of ceftobiprole |
| Q34488329 | Newer antibacterials in therapy and clinical trials |
| Q37942654 | Will new antimicrobials overcome resistance among Gram-negatives? |
Search more.